Showing 1 - 4 results of 4 for search 'Marjatta Leirisalo-Repo', query time: 0.03s Refine Results
  1. 1
    Baseline JAK phosphorylation profile of peripheral blood leukocytes, studied by whole blood phosphospecific flow cytometry, is associated with 1-year treatment response in early rheumatoid arthritis

    Baseline JAK phosphorylation profile of peripheral blood leukocytes, studied by whole blood phosphospecific flow cytometry, is associated with 1-year treatment response in early rh... by Krista Kuuliala, Antti Kuuliala, Riitta Koivuniemi, Hannu Kautiainen, Heikki Repo, Marjatta Leirisalo-Repo

    Published 2017-04-01
    Get full text
    Article
  2. 2
    Constitutive STAT3 Phosphorylation in Circulating CD4+ T Lymphocytes Associates with Disease Activity and Treatment Response in Recent-Onset Rheumatoid Arthritis.

    Constitutive STAT3 Phosphorylation in Circulating CD4+ T Lymphocytes Associates with Disease Activity and Treatment Response in Recent-Onset Rheumatoid Arthritis. by Krista Kuuliala, Antti Kuuliala, Riitta Koivuniemi, Suvi Oksanen, Mari Hämäläinen, Eeva Moilanen, Hannu Kautiainen, Marjatta Leirisalo-Repo, Heikki Repo

    Published 2015-01-01
    Get full text
    Article
  3. 3
    Somatic STAT3 mutations in Felty syndrome: an implication for a common pathogenesis with large granular lymphocyte leukemia

    Somatic STAT3 mutations in Felty syndrome: an implication for a common pathogenesis with large granular lymphocyte leukemia by Paula Savola, Oscar Brück, Thomas Olson, Tiina Kelkka, Markku J. Kauppi, Panu E. Kovanen, Soili Kytölä, Tuulikki Sokka-Isler, Thomas P. Loughran, Marjatta Leirisalo-Repo, Satu Mustjoki

    Published 2018-02-01
    Get full text
    Article
  4. 4
    Glycoprotein YKL-40: A potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and infliximab. Evidence from the randomised controlled NEO-RACo trial.

    Glycoprotein YKL-40: A potential biomarker of disease activity in rheumatoid arthritis during intensive treatment with csDMARDs and infliximab. Evidence from the randomised control... by Tuija Väänänen, Katriina Vuolteenaho, Hannu Kautiainen, Riina Nieminen, Timo Möttönen, Pekka Hannonen, Markku Korpela, Markku J Kauppi, Kari Laiho, Oili Kaipiainen-Seppänen, Riitta Luosujärvi, Tea Uusitalo, Toini Uutela, Marjatta Leirisalo-Repo, Eeva Moilanen, NEO-RACo Study Group

    Published 2017-01-01
    Get full text
    Article

Search Tools: